Form 4: Zenas BioPharma CEO Boosts Stake with $1M Stock Purchase

Zenas BioPharma's CEO and Chairman, Leon O. Moulder Jr., increased his beneficial ownership by purchasing 54,000 shares of common stock in late March 2026.

Summary

• Leon O. Moulder Jr., CEO and Chairman of Zenas BioPharma, Inc. (ZBIO), acquired a total of 54,000 shares of common stock.
• On March 30, 2026, 20,000 shares were purchased at a weighted average price of $18.23 per share, with prices ranging from $18.195 to $18.25.
• On March 31, 2026, an additional 34,000 shares were purchased at a weighted average price of $19.31 per share, with prices ranging from $18.84 to $19.58.
• These transactions were executed pursuant to a Rule 10b5-1(c) plan.
• Following these transactions, Mr. Moulder's total beneficial ownership includes 1,726,039 shares indirectly held through Tellus BioVentures LLC, 36,928 shares indirectly held through the Leon O. Moulder, Jr. Revocable Trust, and 423,155 shares held directly.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal. Significant insider buying by the CEO and Chairman, especially under a 10b5-1 plan, indicates high confidence in Zenas BioPharma's future performance and potential undervaluation.

Positives

• The CEO and Chairman, Leon O. Moulder Jr., increased his beneficial ownership in Zenas BioPharma by purchasing 54,000 shares, signaling confidence in the company's future.
• The transactions were made under a Rule 10b5-1(c) plan, indicating a pre-planned investment strategy.

Future Outlook

This Form 4 filing does not contain explicit forward-looking statements or guidance, as its primary purpose is to report insider transactions. However, the insider purchases may implicitly signal management's positive outlook on the company's future performance.

Management Comments

• Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
• The reporting person is a Trustee of the Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008 and may be deemed to have voting and dispositive power over the shares held by the Trust. The reporting person is the Issuer's chief executive officer and Chairman of its board of directors. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider buying, especially by a CEO and Chairman, can often be interpreted by the market as a strong vote of confidence in the company's prospects within the competitive biopharma industry. Such actions can sometimes precede positive developments or reflect an insider's belief that the stock is undervalued.

Comparison to Industry Standards

• Insider buying by a CEO and Chairman is generally viewed positively, aligning with best practices for demonstrating alignment of interests between management and shareholders.
• While specific comparable companies or projects are not mentioned in this filing, significant insider purchases in the biopharma sector, such as those seen with executives at companies like Moderna or Pfizer during key development phases, often correlate with strong belief in pipeline success or market potential.
• The total value of these purchases, approximately $1 million, represents a notable personal investment by the CEO, which is a substantial commitment compared to typical open-market purchases by executives in companies of similar market capitalization.

Stakeholder Impact

• Shareholders: May view the CEO's increased stake as a positive indicator of management confidence, potentially boosting investor sentiment.
• Employees: Could interpret the insider buying as a sign of stability and positive future prospects for the company.

Key Dates

Recommendation

The significant open-market purchases by Zenas BioPharma's CEO and Chairman, Leon O. Moulder Jr., totaling 54,000 shares at prices up to $19.58, represent a strong vote of confidence in the company's valuation and future prospects. This insider buying, especially from a key executive, suggests that management believes the stock is currently undervalued or poised for growth. Such actions often precede positive company developments or reflect a deep conviction in the strategic direction and operational execution. For a seasoned investor, this signals a favorable risk-reward profile, warranting a 'buy' recommendation.

Keywords

Zenas BioPharma, ZBIO, Insider Trading, Stock Purchase, CEO, Leon O. Moulder Jr., Form 4, Beneficial Ownership, Biopharma